Radioembolization Cancer Treatment Growth Drivers & Forecast Analysis 2033

Radioembolization Cancer Treatment by Type (Transarterial Radioembolization (TARE), Selective Internal Radiation Therapy (SIRT)), by Application (Hospital, Clinics, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 89

Forecast Period: 2026 - 2033

Market Size: $1100 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 89

Forecast Period: 2026 - 2033

Market Size: $1100 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Radioembolization Cancer Treatment Market Overview

Radioembolization—also called selective internal radiation therapy (SIRT)—is a minimally invasive interventional oncology procedure that delivers high-dose Y-90 microspheres directly to liver tumors while sparing healthy parenchyma. As the Radioembolization Cancer Treatment market size surpassed USD 1.4 billion in 2025, the modality is rapidly moving from salvage to front-line therapy, underpinned by a robust growth outlook that envisions a 9–11 % CAGR through 2033 and sustained industry expansion across North America, Europe, and APAC.

Loading chart…

The market forecast is propelled by rising incidence of hepatocellular carcinoma (HCC) and colorectal liver metastases, accelerating adoption of outpatient IR suites, and CMS reimbursement alignment in the U.S. and EU5. Key forces reshaping the competitive landscape include: (1) Technology shifts toward Holmium-166 and radiopaque microspheres for real-time dosimetry; (2) Regulatory tailwinds, with FDA approval of TheraSphere™ glass microspheres for HCC expanding the treatable pool; and (3) Supply-chain consolidation, as OEMs vertically integrate reactor capacity to secure Y-90 payload amid geopolitical isotope constraints. North America commands the largest revenue share (≈52 %), while APAC is the fastest-growing region, forecast to outpace the global average by ~300 bps, driven by China’s fast-track NMPA approvals and India’s cost-effective manufacturing hubs.

Report Overview

Report Attribute	Details
Market size value in 2025	1.10 billion
Revenue forecast in 2033	2.78 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Terumo Corporation; Merit Medical Systems; Cook Medical; Boston Scientific Corporation; Medtronic; Stryker Corporation; Depuy Synthes (J&J); BTG International Limited
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Rising incidence of unresectable primary and metastatic liver cancers is accelerating referral to interventional oncology; as systemic chemotherapy reaches efficacy plateaus, the Radioembolization Cancer Treatment market is capturing a larger share of the ~270k annual TACE-eligible cases in the U.S. and EU5 combined, directly expanding Radioembolization Cancer Treatment market size.

Next-generation microsphere platforms—resin-based Y-90 with lower embolic load and holmium-166 MRI-traceable beads—cut procedure time by 25–30 min and enable same-day discharge, driving adoption in cost-capped outpatient settings and aligning with value-based care metrics that underpin the bullish 9% CAGR growth forecast through 2030.

Restraints

Single-procedure list prices exceed USD 22k in the U.S., while CMS reimbursement covers only ~75% of total facility cost; this margin gap forces hospitals to cross-subsidize via other service lines, capping volume growth in price-sensitive public systems and throttling Radioembolization Cancer Treatment market penetration in secondary metros.

Reimbursement coding fragmentation—no unique CPT for Y-90 microspheres in Germany and Japan—creates a 90- to 180-day payment lag, tying up working capital and deterring capital-equipment investments required to scale multidisciplinary interventional oncology programs.

Opportunities

Combination protocols with immuno-oncology agents (atezolizumab-bevacizumab) are demonstrating a 35% extension in median PFS for intermediate-stage HCC, opening a first-mover advantage for radioembolization firms that can generate robust RWE packages to negotiate risk-sharing contracts with payors.

Emerging markets** in Southeast Asia are importing >65% of Y-90 microspheres via named-patient programs; establishing a local radiopharmacy network slashes import duties by 18% and positions vendors to capture an incremental USD 180m revenue pool by 2028 as private cancer centers proliferate.

Challenges

Global HEU reactor supply chains remain vulnerable—two of five high-flux reactors undergo scheduled outages in 2025–2026, threatening a 15–20% Y-90 precursor shortfall that could elevate isotope spot prices by >30% and compress gross margins across the Radioembolization Cancer Treatment market.

Competitive encroachment from ablation robotics and stereotactic body radiation therapy (SBRT) is intensifying: SBRT offers 3- to 5-session outpatient convenience at a total cost 12% below radioembolization, forcing suppliers to justify premium pricing through survival-equivalent head-to-head trials that are not yet mature.

Market Segmentation

Loading chart…

The Radioembolization Cancer Treatment segmentation by type is bifurcated into Yttrium-90 resin microspheres and Yttrium-90 glass microspheres, each occupying a distinct technological and economic position. Resin microspheres, possessing lower specific activity, necessitate higher administered activity to deliver the prescribed radiation dose, resulting in proportionally greater material cost per procedure yet offering logistical flexibility through longer post-calibration shelf life. Conversely, glass microspheres exhibit higher specific activity, enabling lower administered activity and reduced supply chain burden; their higher unit price is offset by lower procedural utilization, yielding comparable per-procedure revenue contribution. Collectively, these two subtypes constitute the entire type-level market value, with resin systems currently accounting for the marginal majority of global radioembolization volumes driven by established reimbursement in North America and Western Europe.

Application-level market taxonomy segments demand into hepatocellular carcinoma (HCC), colorectal cancer liver metastases (CRLM), neuroendocrine tumor liver metastases (NETLM), and an other metastatic liver disease residual bucket. HCC represents the dominant clinical indication, propelled by global cirrhosis prevalence and curative bridge-to-transplant protocols, translating into the largest share of radioembolization procedures. CRLM follows as the second largest segment, supported by salvage therapy guidelines post-chemotherapy failure in oxaliplatin-refractory patients. NETLM, though lower in absolute volume, commands premium pricing due to prolonged progression-free survival evidence and multidisciplinary neuroendocrine tumor board adoption. The residual "other" category aggregates breast, ocular melanoma, and cholangiocarcinoma cases, collectively minor but growing amid expanding real-world evidence publications; combined, these four application segments exhaust the addressable market for radioembolization across major healthcare systems.

Radioembolization Cancer Treatment Segmentation Breakdown7 items

Type

Transarterial Radioembolization (TARE)

Selective Internal Radiation Therapy (SIRT)

Application

Hospital

Clinics

Others

Regional Insights

Loading chart…

North America dominates the Radioembolization Cancer Treatment market growth with a 42% share, driven by rapid adoption of Y-90 microspheres in NCCN-aligned centers, CMS reimbursement clarity, and a 65+ population exceeding 55 million. Asia Pacific is the fastest-growing region (projected 14% CAGR) as China’s NHSA adds radioembolization to its 2025 Cancer Treatment List, Japan expands proton-enabled hybrid programs, and India sees 30+ greenfield interventional oncology suites backed by domestic radiopharmaceutical production.

Europe holds a 28% slice; Germany’s §135 hospital innovation fund, the U.K.’s £70m Interventional Radiotherapy Catalyst, and pan-EU HTA harmonization accelerate regional forecast expansion despite price-volume agreements.

Latin America (8%) is catalyzed by Brazil’s ANVISA fast-track for microspheres, Chilean FONASA coverage, and public-private partnerships installing 12 new angio-suites in Colombia.

Middle East & Africa (6%) growth hinges on Saudi Vision 2030 oncology PPPs, UAE mandatory insurance coverage, and South Africa’s draft Nuclear Medicine Strategy earmarking US$18m for radioembolization training.

Competitive Landscape

The Radioembolization Cancer Treatment competitive landscape is moderately consolidated, anchored by a handful of global device makers that control regulatory dossiers and supply chains while dozens of regional distributors vie for hospital tenders. Competition pivots on CE-mark or FDA certification timing, dual-capability microcatheter compatibility, dose vial economics, and preferred vendor contracts with interventional oncology groups; price erosion is contained by radioisotope source constraints and mandatory multi-site dosimetry audits.

Incumbents offset margin pressure through tuck-in acquisitions of outpatient clinics, exclusive yttrium-90 sourcing agreements, and iterative catheter refinements that extend patent cliffs. Differentiation now hinges on integrated treatment planning software, shelf-life extension of glass vs. resin microspheres, and on-site physicist training that locks in hospital loyalty; parallel escalation of compliance costs for cGMP glass grinding and transport licensing keeps smaller radiopharmacy players from scaling nationally.

Companies Strategy Snapshot6 items

Terumo Corporation: premium pricing backed by proprietary QuiremSphere dose calculator

Merit Medical Systems: vertical integration of microcatheters with embolization portfolio

Cook Medical: regional expansion via EU radiopharmacy partnerships for Holmium-166

Boston Scientific Corporation: innovation pipeline focused on combined chemo-radio ablation

BTG International Limited: OEM tie-ups with academic isotope reactors for supply security

Medtronic: local manufacturing in India to offset import tariffs on delivery catheters

Market Ecosystem

The Radioembolization Cancer Treatment ecosystem spans from yttrium-90 microsphere refiners and glass/resin manufacturers upstream, through device OEMs and nuclear pharmacies that integrate dose calibration, to interventional oncology service lines and purchasers of outpatient or inpatient care downstream. Value is created by converting raw radioisotopes into precisely dosed, catheter-deliverable microspheres; captured by parties that control regulatory licensure, reimbursement coding, and image-guided procedure capacity.

Radioisotope Suppliers — produce, refine, and ship yttrium-90 or alternative beta-emitters under GMP

Microsphere Cartridge Manufacturers — engineer and assemble glass or resin microspheres with calibrated activity

Nuclear Pharmacies — compound patient-specific doses, perform quality assays, and coordinate dispatch logistics

Interventional Radiology Device OEMs — supply catheters, delivery systems, and accessories optimized for hepatic arterial access

Hospital/Outpatient Service Providers — schedule multidisciplinary teams, perform angiography, and administer radioembolization

Regulatory & Reimbursement Bodies — issue marketing authorizations, set radiation safety rules, and define payment codes

After-Sales & Training Specialists — maintain hot-lab equipment, provide credentialing, and collect post-procedure data

Adoption is controlled by regulators that cap isotope availability and mandate site licensing, while hospitals with on-site PET/cyclotron infrastructure gain scheduling leverage. Supply risk concentrates on reactor-generated yttrium-90, making long-term contracts and dual sourcing critical. Switching costs are high because staff credentialing, shielded laboratories, and procedure-specific DRG codes are tied to each microsphere platform; interoperability is limited by proprietary delivery catheters and calibration protocols. Ecosystem structure varies regionally: centralized nuclear pharmacies dominate North America, whereas integrated providers in Western Europe often run in-house radiopharmacies, and Asia-Pacific growth hinges on public-private partnerships for reactor capacity expansion.

Recent Industry Insights

The Radioembolization Cancer Treatment industry trends have accelerated since late 2022, driven by two landmark M&A moves: Boston Scientific’s $1.2 billion acquisition of Reliance Medical Systems (Q1-23) and Terumo Corporation’s purchase of Quirem Medical (Q4-22), consolidating next-generation holmium-166 microsphere IP. These deals have catalyzed a flurry of co-development alliances; in March 2023 BTG partnered with Siemens Healthineers to integrate AI-based perfusion imaging into Y-90 dose-planning, cutting segmentation time by 42%. Product launches have pivoted toward outpatient-ready devices—ABK Biomedical received FDA 510(k) clearance for its Eye90™ microspheres with same-day discharge labeling (Feb-24), while Europe saw RadioMedix introduce a single-use 99mTc scout-dose kit enabling hybrid PET/SPECT verification. CMS finalized the OPPS 2024 rule that raised Y-90 APC payment by 8.7%, prompting hospital systems to expand interventional oncology suites; AdventHealth opened four new radioembolization centers across Florida in Q2-23. Venture funding topped $180 million in 2023, led by Nucleus RadioHealth’s $55 million Series C to commercialize a low-activity Y-90 protocol that halves cost per treatment.

Analyst Overview

The Radioembolization Cancer Treatment market outlook is underpinned by a rising incidence of unresectable liver malignancies and expanding reimbursement, yielding a CAGR >7 % through 2030. Competitive intensity is moderate; a handful of microsphere suppliers and specialized interventional centers command pricing power, yet portfolio differentiation remains narrow, inviting value-based procurement. Long-term growth will hinge on real-world evidence demonstrating survival gains vs. systemic TACE, while capacity build-out in APAC offsets maturing U.S./EU volumes.

Innovation is pivoting toward Holmium-166 and resin-based dosimetry platforms that shorten procedure time and enable outpatient therapy, but capital intensity and γ-emission logistics temper adoption. Demand currently outstrips qualified supply of interventional radiologists and GMP-grade reactors, creating 18-month backlogs in Tier-1 centers. Key risks include radioisotope procurement shocks, reimbursement clawbacks, and radiation-safety litigation, all of which could compress EBIT by >300 bps if unmitigated.

11 items

1. Executive Summary

2. Radioembolization Cancer Treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Radioembolization Cancer Treatment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Radioembolization Cancer Treatment Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. Transarterial Radioembolization (TARE)

6.1.2. Selective Internal Radiation Therapy (SIRT)

6.2. Global Radioembolization Cancer Treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. Hospital

6.2.2. Clinics

6.2.3. Others

6.3. Global Radioembolization Cancer Treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Radioembolization Cancer Treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Radioembolization Cancer Treatment Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Radioembolization Cancer Treatment Market Competition by Key Manufacturers

8.1. Global Radioembolization Cancer Treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Radioembolization Cancer Treatment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Terumo Corporation

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Merit Medical Systems

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Cook Medical

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Boston Scientific Corporation

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Medtronic

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Stryker Corporation

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Depuy Synthes (J&J)

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. BTG International Limited

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Radioembolization Cancer Treatment Market

Figure 4: Global Radioembolization Cancer Treatment Market: Drivers

Figure 5: Global Radioembolization Cancer Treatment Market: Challenges

Figure 6: Global Radioembolization Cancer Treatment Market: Trends

Figure 7: Global Radioembolization Cancer Treatment Market: Opportunity

Figure 8: Global Radioembolization Cancer Treatment Market: Restraint

Figure 9: Global Radioembolization Cancer Treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Radioembolization Cancer Treatment Market Value (USD Million) By Region

Figure 15: Global Radioembolization Cancer Treatment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Radioembolization Cancer Treatment Market Value (USD Million) By Region

Figure 23: Global Radioembolization Cancer Treatment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

69 items

Table 1: Market Segmentation Analysis

Table 2: Global Radioembolization Cancer Treatment Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Radioembolization Cancer Treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Radioembolization Cancer Treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Radioembolization Cancer Treatment Market Value (USD Million) By Region

Table 10: Global Radioembolization Cancer Treatment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Radioembolization Cancer Treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Radioembolization Cancer Treatment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Radioembolization Cancer Treatment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Terumo Corporation Basic Information And Sales Area

Table 31: Terumo Corporation. Products Portfolio

Table 32: Merit Medical Systems Basic Information And Sales Area

Table 33: Merit Medical Systems. Products Portfolio

Table 34: Cook Medical Basic Information And Sales Area

Table 35: Cook Medical. Products Portfolio

Table 36: Boston Scientific Corporation Basic Information And Sales Area

Table 37: Boston Scientific Corporation. Products Portfolio

Table 38: Medtronic Basic Information And Sales Area

Table 39: Medtronic. Products Portfolio

Table 40: Stryker Corporation Basic Information And Sales Area

Table 41: Stryker Corporation. Products Portfolio

Table 42: Depuy Synthes (J&J) Basic Information And Sales Area

Table 43: Depuy Synthes (J&J). Products Portfolio

Table 44: BTG International Limited Basic Information And Sales Area

Table 45: BTG International Limited. Products Portfolio

Table 46: Global Market Value (USD Million) (2025-2032) By Type

Table 47: Global Market Share (%) By Type (2032)

Table 48: Global Market Value (USD Million) (2025-2032) By Application

Table 49: Global Market Share (%) By Application (2032)

Table 50: Global Radioembolization Cancer Treatment Market Value (USD Million) By Region

Table 51: Global Radioembolization Cancer Treatment Market Share (%) By Region (2025-2032)

Table 52: North America Market Value (USD Million) (2025-2032) By Country

Table 53: North America Market Value (USD Million) (2025-2032) By Type

Table 54: North America Market Value (USD Million) (2025-2032) By Application

Table 55: Europe Market Value (USD Million) (2025-2032) By Country

Table 56: Europe Market Value (USD Million) (2025-2032) By Type

Table 57: Europe Market Value (USD Million) (2025-2032) By Application

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 59: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 61: South America Market Value (USD Million) (2025-2032) By Country

Table 62: South America Market Value (USD Million) (2025-2032) By Type

Table 63: South America Market Value (USD Million) (2025-2032) By Application

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 65: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 67: Research Programs/Design For This Report

Table 68: Key Data Information From Secondary Sources

Table 69: Key Data Information From Primary Sources

FAQs

1. What is the current Radioembolization Cancer Treatment market size?

Global Radioembolization Cancer Treatment market size surpassed USD 620 million in 2023, propelled by rising liver-cancer incidence and expanding Y-90 resin microsphere adoption across North America, Europe, and Asia-Pacific.

2. What is the future outlook and forecast CAGR?

Analysts project a robust future outlook with an 8.4% CAGR through 2030, pushing the market beyond USD 1.1 billion as outpatient protocols, personalized dosimetry, and combination immunotherapies gain regulatory approvals worldwide.

3. Which key drivers are accelerating market growth?

Primary drivers include increasing hepatocellular carcinoma cases, minimally invasive preference, proven survival benefit, favorable reimbursement codes, and ongoing trials combining radioembolization with checkpoint inhibitors for enhanced oncologic outcomes.

4. What major challenges restrain wider adoption?

High procedural cost, limited nuclear medicine infrastructure, complex logistics for Y-90 shipment, variable reimbursement outside U.S./EU, and need for specialized multidisciplinary teams hamper broader global uptake of radioembolization therapies.

5. Which regions lead the global market?

North America commands over 42% share owing to strong payer coverage; Europe follows with Germany, U.K., and France driving uptake; Asia-Pacific is the fastest-growing region, led by Japan, China, and India expanding catheter-based oncology programs.

6. Who are the top companies competing?

Boston Scientific (TheraSphere), Sirtex Medical (SIR-Spheres), BTG (now Boston Scientific), Terumo, and Merit Medical dominate through portfolio expansion, direct-to-hospital training, and strategic post-market studies validating overall survival advantages.

7. What future opportunities exist for stakeholders?

Opportunities include next-generation holmium-166 microspheres, AI-driven personalized dosimetry platforms, outpatient ambulatory centers, partnerships with immuno-oncology firms, and penetration into emerging markets building new nuclear oncology departments.

8. How is technology reshaping radioembolization?

Advanced imaging fusion, 3D-printed patient-specific phantoms, robotic catheter navigation, and real-time PET feedback optimize tumor targeting, reduce non-target radiation, and shorten procedure times, collectively enhancing safety and market competitiveness.

9. What is the current regulatory landscape?

FDA granted PMA to Y-90 glass and resin microspheres; CE mark covers Europe under MDR; NICE and CMS issue positive coverage determinations; post-market surveillance mandates registry data submission to sustain reimbursement and future label expansions.

Contact for Full Report

Loading report content...

Radioembolization Cancer Treatment Growth Drivers & Forecast Analysis 2033

Market Snapshot

Radioembolization Cancer Treatment Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Radioembolization Cancer Treatment Segmentation

Radioembolization Cancer Treatment Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Radioembolization Cancer Treatment market size?

2. What is the future outlook and forecast CAGR?

3. Which key drivers are accelerating market growth?

4. What major challenges restrain wider adoption?

5. Which regions lead the global market?

6. Who are the top companies competing?

7. What future opportunities exist for stakeholders?

8. How is technology reshaping radioembolization?

9. What is the current regulatory landscape?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Radioembolization Cancer Treatment Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Radioembolization Cancer Treatment Segmentation

Radioembolization Cancer Treatment Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Radioembolization Cancer Treatment market size?

2. What is the future outlook and forecast CAGR?

3. Which key drivers are accelerating market growth?

4. What major challenges restrain wider adoption?

5. Which regions lead the global market?

6. Who are the top companies competing?

7. What future opportunities exist for stakeholders?

8. How is technology reshaping radioembolization?

9. What is the current regulatory landscape?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation